背景:与光子相比,碳离子放射疗法(C-离子RT)在癌症治疗中提供了更好的剂量分布。此外,碳离子束提供了更高的生物有效性,因此肿瘤控制概率更高。然而,关于C-离子RT中危险器官的剂量限制的信息有限.这项研究旨在确定碳离子C-离子RT治疗子宫癌后直肠和膀胱晚期发病率的预测因素。
方法:在1995年6月至2010年1月期间,134例子宫癌患者接受了具有治愈性目的的C-离子RT治疗;处方剂量为52.8-74.4Gy(相对生物学有效性),分20-24次。在这些病人中,对132例随访时间>6个月的患者进行分析。我们将数据分为两个小组,24个分数组和20个分数组。晚期发病率,直肠炎,根据肿瘤放射治疗组/欧洲癌症研究和治疗组织标准评估膀胱炎.临床和剂量学参数的相关性,V10-V60,D5cc,D2cc,和Dmax,对≥1级发病率进行回顾性分析。
结果:在24个分数组中,≥1级直肠和膀胱疾病的3年精算发生率分别为64%和9%,分别。此外,在20个分数组中,≥1级直肠和膀胱疾病的3年精算发生率分别为32%和19%,分别。关于直肠的剂量-体积直方图数据,≥1级直肠炎患者的D5cc和D2cc显著高于无发病者.此外,≥1级膀胱炎患者的膀胱D5cc显著高于无发病率者.单因素分析结果表明,直肠D2cc与≥1级晚期直肠炎的发展相关。此外,膀胱D5cc与≥1级晚期膀胱炎的发展相关。
结论:本研究确定了C-离子RT中关于直肠和膀胱晚期发病率发生的剂量-体积关系。本文讨论的因素的评估将有益于预防盆腔恶性肿瘤的C-离子RT后的晚期发病率。
背景:回顾性注册(NIRS:16-040)。
BACKGROUND: Carbon-ion radiotherapy (C-ion RT) provides better dose distribution in cancer treatment compared to photons. Additionally, carbon-ion beams provide a higher biological effectiveness, and thus a higher tumor control probability. However, information regarding the dose constraints for organs at risk in C-ion RT is limited. This study aimed to determine the predictive factors for late morbidities in the rectum and bladder after carbon-ion C-ion RT for uterus carcinomas.
METHODS: Between June 1995 and January 2010, 134 patients with uterus carcinomas were treated with C-ion RT with curative intent; prescription doses of 52.8-74.4 Gy (relative biological effectiveness) were delivered in 20-24 fractions. Of these patients, 132 who were followed up for > 6 months were analyzed. We separated the data in two subgroups, a 24 fractions group and a 20 fractions group. Late morbidities, proctitis, and cystitis were assessed according to the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer criteria. The correlations of clinical and dosimetric parameters, V10-V60, D5cc, D2cc, and Dmax, with the incidence of ≥grade 1 morbidities were retrospectively analyzed.
RESULTS: In the 24 fractions group, the 3-year actuarial occurrence rates of ≥grade 1 rectal and bladder morbidities were 64 and 9%, respectively. In addition, in the 20 fractions group, the 3-year actuarial occurrence rates of ≥grade 1 rectal and bladder morbidities were 32 and 19%, respectively. Regarding the dose-volume histogram data on the rectum, the D5cc and D2cc were significantly higher in patients with ≥grade 1 proctitis than in those without morbidity. In addition, the D5cc for the bladder was significantly higher in patients with ≥grade 1 cystitis than in those without morbidity. Results of univariate analyses showed that D2cc of the rectum was correlated with the development of ≥grade 1 late proctitis. Moreover, D5cc of the bladder was correlated with the development of ≥grade 1 late cystitis.
CONCLUSIONS: The present study identified the dose-volume relationships in C-ion RT regarding the occurrence of late morbidities in the rectum and bladder. Assessment of the factors discussed herein would be beneficial in preventing late morbidities after C-ion RT for pelvic malignancies.
BACKGROUND: Retrospectively registered ( NIRS: 16-040 ).